ClinicalTrials.gg
CompletedNCT02505919WATERUpdated Jul 3, 2023Results posted

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

An interventional study of AQUABEAM System and Transurethral Resection of the Prostate (TURP) in Benign Prostatic Hyperplasia (BPH), sponsored by PROCEPT BioRobotics. Completed at 17 sites in 4 countries. Open to male participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by PROCEPT BioRobotics · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Enrollment
50th of 150
184 · median 83
Started
2015
with 7 others
No phase
63 of 188
13 open now
Registered
92nd of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 50th largest by enrollment of the 150 interventional ones that give a count, is one of 8 that started in 2015, is one of 63 with no phase, and was the 92nd registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS). The primary endpoints for safety and effectiveness were measured at 3 and 6 months, respectively, and subjects were followed out to 5 years to collect long-term clinical data.

03

Conditions studied

  • Benign Prostatic Hyperplasia (BPH)

Keywords

  • Lower Urinary Tract Symptoms (LUTS)
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has diagnosis of lower urinary tract symptoms due to benign prostatic enlargement causing bladder outlet obstruction.
  • Age from 45 to 80 years.
  • Subject has medical record documentation of a prostate volume between 30mL and 80mL (inclusive) by transrectal ultrasound (TRUS). (If TRUS testing documentation is available from less than 180 days prior to the date and the prostate volume is between 30mL and 80mL, it may be used for the inclusion/exclusion criteria.)
  • Subject has an International Prostate Symptom Score (IPSS) score greater than or equal to 12 measured at the baseline visit.
  • Subject has medical record documentation of a maximum urinary flow rate (Qmax) less than 15mL/s. (If uroflow testing documentation is available within 90 days prior to the informed consent date, and the sample is greater than or equal to 125mL, and the Qmax is less than 15mL/s it may be used for the inclusion/exclusion criteria.)
  • Subject has a serum creatinine that is within the normal range for the laboratory at the study center (or documentation of clinical insignificance in the subject's medical record by the investigator if outside the normal range) and measured ≤ 30 days prior to the date of surgery.
  • History of inadequate response, , or refusal to medical therapy.

Exclusion criteria

Exclusion Criteria:

  • (BMI) ≥ 42.
  • History of prostate cancer or current/suspected bladder cancer.
  • Prostate cancer should be ruled out before participation to the satisfaction of the investigator if Prostate-Specific Antigen (PSA) is above acceptable thresholds.
  • Subjects with a history of actively treated bladder cancer within the past two (2) years.
  • Bladder calculus or bladder diverticulum (e.g., pouch size >20% of full bladder size).
  • Active infection, including urinary tract infection.
  • Prostatitis treated with antibiotics within 1 year of enrollment.
  • Ever been diagnosed with a urethral stricture, meatal stenosis, or bladder neck contracture.
  • Subject has damage to external urinary sphincter .
  • Subject has diagnosis of stress urinary incontinence that requires treatment or daily pad or device use.
  • Post-Void Residual (PVR) > 300 mL.
  • Urinary retention at time of enrollment or subject has been catheterized in the 14 days prior to the surgical procedure.
  • Subject has a history of intermittent self-catheterization.
  • Previous prostate surgery or history of other lower urinary tract surgery such as e.g. urinary diversion, artificial urinary sphincter or penile prosthesis.
  • Subjects on anticoagulants (if medication cannot be stopped before and after procedure) or known coagulopathy (except aspirin below 100mg/d).
  • Any severe illness that would prevent complete study participation or confound study results.
  • Participants using systematic immune-suppressants including ; unable to withhold non-steroidal anti-inflammatory agents (Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin) for 3-5 days prior to treatment except for low dose aspirin (e.g. less than or equal to 100mg).
  • Participants using anticholinergics specifically for bladder problems. Use of medications with anticholinergic properties is allowable provided the patient does not have documented adverse urinary side effects from these medications.
  • to general or spinal anesthesia.
  • Subject has any other disease or condition(s) that would interfere with completion of the study and follow up assessments, would increase risks of the procedure, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect outcomes.
  • Subject is unwilling to accept a transfusion should one be required.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Treatment

    AQUABEAM System

    Device: AQUABEAM System

  • Active comparator
    Active Comparator

    Transurethral Resection of the Prostate (TURP)

    Procedure: Transurethral Resection of the Prostate (TURP)

Interventions

  • DeviceAQUABEAM System

    The AQUABEAM system, a personalized image-guided tissue removal system, utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue.

  • ProcedureTransurethral Resection of the Prostate (TURP)

    Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability)

    The primary safety endpoint is the proportion of subjects with adverse events rated as probably or definitely related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (e.g. ejaculatory disorder or erectile dysfunction) evidenced through 3 months post treatment. Note that the Clavien-Dindo classification scheme is for grading postoperative complications not events that reflect lack of effective treatment. Results are presented as a percentage rounded to the whole number.

    Time frame: Three months post-treatment

  2. Change Score of IPSS Questionnaire Between Baseline and 6 Months

    The primary effectiveness endpoint is the IPSS change score from baseline to 6 months. International Prostate Symptom Score (IPSS) ranges from 0 to 35. A higher score indicates a worse outcome.

    Time frame: Six months post-treatment

Other outcomes

  1. Long-term Effectiveness as Measured by International Prostate Symptom Score (IPSS) at 60 Months

    Change score of International Prostate Symptom Score (IPSS) at 60 months as compared to baseline. Score range is from 0 to 35, with a low score associated with more favorable outcomes. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.

    Time frame: 60 months following original surgical intervention

  2. International Prostate Symptom Score (IPSS) at 60 Months

    International Prostate Symptom Score (IPSS) at 60 months. Score range is from 0 to 35, with a low score associated with more favorable outcomes.

    Time frame: 60 months following original surgical intervention

  3. International Prostate Symptom Score Quality of Life (IPSS-QoL) at 60 Months

    International Prostate Symptom Score Quality of Life (IPSS-QoL) sub-score. Score range is from 0 to 6, with a low score associated with more favorable outcomes.

    Time frame: 60 months following original surgical intervention

  4. Change in Maximum Urinary Flow Rate (Qmax) at 60 Months From Baseline

    Change in Uroflowmetry measurement of voided urine (in milliliters) per unit of time (in seconds) at 60 Months from Baseline. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.

    Time frame: 60 months following original surgical intervention

  5. Change in Post-void Residual (PVR) at 60 Months From Baseline

    Change in Post-void residual (PVR) urine test at 60 Months from Baseline. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.

    Time frame: 60 months following original surgical intervention

07

Results

Posted Apr 8, 2020

Participant flow

Treatment
Participant flow — Treatment
MilestoneTreatmentActive Comparator
Started11665
Completed11665
Not completed00
1 Week Follow-Up
Participant flow — 1 Week Follow-Up
MilestoneTreatmentActive Comparator
Started11665
Completed11665
Not completed00
1 Month Follow-Up
Participant flow — 1 Month Follow-Up
MilestoneTreatmentActive Comparator
Started11665
Completed11665
Not completed00
3 Months Follow-Up
Participant flow — 3 Months Follow-Up
MilestoneTreatmentActive Comparator
Started11665
Completed11665
Not completed00
6 Months Follow-Up
Participant flow — 6 Months Follow-Up
MilestoneTreatmentActive Comparator
Started11665
Completed11663
Not completed02
12 Months Follow-Up
Participant flow — 12 Months Follow-Up
MilestoneTreatmentActive Comparator
Started11663
Completed11561
Not completed12
24 Months Follow-Up
Participant flow — 24 Months Follow-Up
MilestoneTreatmentActive Comparator
Started11561
Completed11260
Not completed31
36 Months Follow-Up
Participant flow — 36 Months Follow-Up
MilestoneTreatmentActive Comparator
Started11260
Completed9755
Not completed155
60 Months Follow-Up
Participant flow — 60 Months Follow-Up
MilestoneTreatmentActive Comparator
Started9755
Completed5832
Not completed3923

Outcome measures

PrimaryProportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability)

The primary safety endpoint is the proportion of subjects with adverse events rated as probably or definitely related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (e.g. ejaculatory disorder or erectile dysfunction) evidenced through 3 months post treatment. Note that the Clavien-Dindo classification scheme is for grading postoperative complications not events that reflect lack of effective treatment. Results are presented as a percentage rounded to the whole number.

Time frame:
Three months post-treatment
Reported as:
Number · percentage of participants
Proportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability)
percentage of participantsTreatmentActive Comparator
Proportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability)26 (18.2 to 34.8)42 (29.4 to 54.4)
PrimaryChange Score of IPSS Questionnaire Between Baseline and 6 Months

The primary effectiveness endpoint is the IPSS change score from baseline to 6 months. International Prostate Symptom Score (IPSS) ranges from 0 to 35. A higher score indicates a worse outcome.

Time frame:
Six months post-treatment
Reported as:
Mean · score on a scale
Change Score of IPSS Questionnaire Between Baseline and 6 Months
score on a scaleTreatmentActive Comparator
Change Score of IPSS Questionnaire Between Baseline and 6 Months-16.9 ± 6.6-15.1 ± 7.9
Other pre-specifiedLong-term Effectiveness as Measured by International Prostate Symptom Score (IPSS) at 60 Months

Change score of International Prostate Symptom Score (IPSS) at 60 months as compared to baseline. Score range is from 0 to 35, with a low score associated with more favorable outcomes. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.

Time frame:
60 months following original surgical intervention
Reported as:
Mean · change in score on a scale
Long-term Effectiveness as Measured by International Prostate Symptom Score (IPSS) at 60 Months
change in score on a scaleTreatmentActive Comparator
Long-term Effectiveness as Measured by International Prostate Symptom Score (IPSS) at 60 Months-15.1 ± 6.6-13.2 ± 8.2
Other pre-specifiedInternational Prostate Symptom Score (IPSS) at 60 Months

International Prostate Symptom Score (IPSS) at 60 months. Score range is from 0 to 35, with a low score associated with more favorable outcomes.

Time frame:
60 months following original surgical intervention
Reported as:
Median · score on a scale
International Prostate Symptom Score (IPSS) at 60 Months
score on a scaleTreatmentActive Comparator
International Prostate Symptom Score (IPSS) at 60 Months5.5 (1 to 28)6 (1 to 28)
Other pre-specifiedInternational Prostate Symptom Score Quality of Life (IPSS-QoL) at 60 Months

International Prostate Symptom Score Quality of Life (IPSS-QoL) sub-score. Score range is from 0 to 6, with a low score associated with more favorable outcomes.

Time frame:
60 months following original surgical intervention
Reported as:
Mean · score on a scale
International Prostate Symptom Score Quality of Life (IPSS-QoL) at 60 Months
score on a scaleTreatmentActive Comparator
International Prostate Symptom Score Quality of Life (IPSS-QoL) at 60 Months1.6 ± 1.41.6 ± 1.5
Other pre-specifiedChange in Maximum Urinary Flow Rate (Qmax) at 60 Months From Baseline

Change in Uroflowmetry measurement of voided urine (in milliliters) per unit of time (in seconds) at 60 Months from Baseline. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.

Time frame:
60 months following original surgical intervention
Reported as:
Mean · mL/s
Change in Maximum Urinary Flow Rate (Qmax) at 60 Months From Baseline
mL/sTreatmentActive Comparator
Change in Maximum Urinary Flow Rate (Qmax) at 60 Months From Baseline8.7 ± 9.16.3 ± 7.5
Other pre-specifiedChange in Post-void Residual (PVR) at 60 Months From Baseline

Change in Post-void residual (PVR) urine test at 60 Months from Baseline. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.

Time frame:
60 months following original surgical intervention
Reported as:
Mean · mL
Change in Post-void Residual (PVR) at 60 Months From Baseline
mLTreatmentActive Comparator
Change in Post-void Residual (PVR) at 60 Months From Baseline-62 ± 86-82 ± 94

Adverse events

Collected over 5 years. Non-serious events are listed at a 1.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment4/116 (3.4%)24/116 (20.7%)75/116 (64.7%)
Active Comparator1/65 (1.5%)14/65 (21.5%)53/65 (81.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventTreatmentActive Comparator
BleedingRenal and urinary disorders4/1164/65
Urinary urgency/frequency/difficulty/leakage (non-procedure-related)Renal and urinary disorders5/1161/65
Cardiac (non-procedure-related)Cardiac disorders4/1162/65
Urinary retentionRenal and urinary disorders3/1162/65
Non-urologicGeneral disorders3/1160/65
Other bleeding (non-procedure-related)General disorders2/1160/65
Urinary tract infection (non-procedure-related)Renal and urinary disorders2/1160/65
Bladder neck contracture (non-procedure-related)Renal and urinary disorders1/1161/65
Penial infection (non-procedure-related)Infections and infestations0/1161/65
Prostate cancer (non-procedure-related)Neoplasms benign, malignant and unspecified (incl cysts and polyps)0/1161/65
Most frequent other events
Showing 10 of 36
Most frequent other events
EventTreatmentActive Comparator
Retrograde ejaculationReproductive system and breast disorders8/11616/65
Urinary urgency/frequency/difficulty/leakage (non-procedure-related)Renal and urinary disorders18/11614/65
Urinary urgency/frequency/difficulty/leakageRenal and urinary disorders9/1169/65
Non-urologicGeneral disorders16/1167/65
DysuriaRenal and urinary disorders14/1166/65
BleedingRenal and urinary disorders12/1166/65
Urinary tract infectionRenal and urinary disorders11/1165/65
Erectile Dysfunction (non-procedure-related)Reproductive system and breast disorders7/1166/65
Bleeding (non-procedure-related)Renal and urinary disorders5/1165/65
Urinary retention (non-procedure-related)Renal and urinary disorders4/1165/65

Baseline characteristics

Age, Continuous
Age, Continuous(years)TreatmentActive ComparatorTotal
Mean66.0 ± 7.365.8 ± 7.265.9 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)TreatmentActive ComparatorTotal
Female000
Male11767184
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TreatmentActive ComparatorTotal
Hispanic or Latino336
Not Hispanic or Latino11464178
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TreatmentActive ComparatorTotal
Asian325
Hispanic235
Black224
White10959168
Other101
NA011
Region of Enrollment
Region of Enrollment(Participants)TreatmentActive ComparatorTotal
New Zealand11920
United States613293
United Kingdom321850
Australia13821
08

Study locations

17 sites
  • Urology Centers of Alabama
    Birmingham, Alabama 35209, United States
  • San Diego Clinical Trials
    La Mesa, California 91942, United States
  • University of Southern California, Institute of Urology
    Los Angeles, California 90089, United States
  • Urology Associates, P.C.
    Englewood, Colorado 80113, United States
  • Adult & Pediatric Urology P.C.
    Omaha, Nebraska 68114, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390-9110, United States
  • Houston Metro Urology
    Houston, Texas 77030, United States
  • University of Vermont College of Medicine
    Burlington, Vermont 05401, United States
  • Virginia Urology
    Richmond, Virginia 23235, United States
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
  • Tauranga Urology Research Ltd.
    Tauranga, 3112, New Zealand
  • Frimley Park Hospital
    Frimley, Surrey GU16 7UJ, United Kingdom
  • Princess of Wales Hospital
    Bridgend, Wales CF31 1RQ, United Kingdom
  • Addenbrooke's Treatment Center
    Cambridge, CB2 0QQ, United Kingdom
09

References and documents

Publications

  • Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Kaufman RP Jr, Trainer A, Arther A, Badlani G, Plante M, Desai M, Doumanian L, Te AE, DeGuenther M, Roehrborn C. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation(R) vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. J Urol. 2018 May;199(5):1252-1261. doi: 10.1016/j.juro.2017.12.065. Epub 2018 Jan 31. PubMed 29360529 ↗
  • Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Roehrborn C. Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes. Urology. 2019 Mar;125:169-173. doi: 10.1016/j.urology.2018.12.002. Epub 2018 Dec 12. PubMed 30552937 ↗
  • Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Kaufman RP Jr, Trainer A, Arther A, Badlani G, Plante M, Desai M, Doumanian L, Te AE, DeGuenther M, Roehrborn C. Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Adv Ther. 2019 Jun;36(6):1326-1336. doi: 10.1007/s12325-019-00952-3. Epub 2019 Apr 26. PubMed 31028614 ↗
  • Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Kaufman RP Jr, Trainer A, Arther A, Badlani G, Plante M, Desai M, Doumanian L, Te AE, DeGuenther M, Roehrborn C. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079. PubMed 32065861 ↗
  • Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Kaufman RP Jr, Badlani G, Plante M, Desai M, Doumanian L, Te AE, Roehrborn CG. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol. 2022 Feb;29(1):10960-10968. PubMed 35150215 ↗
  • Pimentel MA, Yassaie O, Gilling P. Urodynamic Outcomes After Aquablation. Urology. 2019 Apr;126:165-170. doi: 10.1016/j.urology.2019.01.020. Epub 2019 Feb 2. PubMed 30721737 ↗
  • Chughtai B, Thomas D. Pooled Aquablation Results for American Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia in Large Prostates (60-150 cc). Adv Ther. 2018 Jun;35(6):832-838. doi: 10.1007/s12325-018-0722-0. Epub 2018 Jun 5. PubMed 29873008 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Jul 2017, 20 months.

Results were first posted in Apr 2020, 2 years 8 months after primary completion.

Of 52 industry-sponsored interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's 20 months is below that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2015
First posted
Jul 22, 2015
StartActual
Oct 30, 2015
Primary completionActual
Jul 14, 2017
CompletionActual
Dec 16, 2021
Results first posted
Apr 8, 2020
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02505919
Lead sponsor
PROCEPT BioRobotics
Responsible party
Sponsor
First posted
Jul 22, 2015
Start date
Oct 30, 2015
Primary completion
Jul 14, 2017
Completion
Dec 16, 2021
Results posted
Apr 8, 2020
Last update
Jul 3, 2023

Study contacts

Peter Gilling, M.D.
principal investigator · Urology BOP
Claus Roehrborn, M.D.
principal investigator · UT Southwestern Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion